Customer Service – Page 4

Ensurge Micropower ASA – Q1 2024

Written by Customer Service on May 14, 2024. Posted in Earnings Releases And Operating Results.

The Ensurge Micropower Q1 2024 is attached. Terje Rogne, the chairman, will host a presentation at the Ensurge Annual General Meeting May 14, 2024, at approximately 0930 CET. Please see the company announcement on May 13, 2024 at 18:00 CET for instructions regarding how to join the presentation. About Ensurge Micropower Ensurge is Energizing Innovation(TM) with the first ultrathin, flexible, reliable, and fundamentally safe solid-state lithium microbattery for the 1 to 100 milliampere-hour (mAh) class of wearable devices, connected sensors, and beyond. The innovative Ensurge Microbattery enables energy-dense rechargeable products that are ideal for form-factor-constrained applications including hearables (hearing aids and wireless headphones), digital and health wearables, sports and fitness devices, and IoT sensor solutions that use...

Q1 2024 Financial Results

Written by Customer Service on May 14, 2024. Posted in Earnings Releases And Operating Results.

Toronto Ontario, May 14, 2024 (GLOBE NEWSWIRE) — (“Amaroq” or the “Corporation” or the “Company”) Q1 2024 Financial Results TORONTO, ONTARIO – 14 May 2024 – Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ Iceland: AMRQ), an independent mine development company with a substantial land package of gold and strategic mineral assets in Southern Greenland, presents its Q1 2024 financials. A conference call for analysts and investors will be held today at 16:00 BST (15:00 GMT, 11:00 EST), details of which can be found further down in this announcement. All dollar amounts are expressed in Canadian dollars unless otherwise noted. Eldur Olafsson, CEO of Amaroq, commented: “During the quarter we successfully completed a fundraise to accelerate mining at Nalunaq, whilst continuing to invest in our wider gold and strategic minerals portfolio...

Report for the three months ended 31 March 2024

Written by Customer Service on May 14, 2024. Posted in Earnings Releases And Operating Results.

Highlights Power generation in the first quarter amounted to 274 GWh, which is a record high quarterly production for the Company. Sale of the 50 percent interest in the non-core Leikanger hydropower plant in April 2024 for MEUR 53, demonstrating the value of the Company’s underlying asset base and enabling recycling of capital into higher return opportunities. Acquired a greenfield portfolio in January 2024 of up to 180 MW of wind and battery projects in Finland, with land secured for all wind turbine locations and initiation of the first permitting process during the first quarter. Continued to mature the greenfield portfolio, including signing binding land agreements for the first 500 MW of solar and battery projects in Germany and progressing pre-permit work in Germany and in the UK. Consolidated financials – 3 months Cash flows...

The Agfa-Gevaert Group in Q1 2024: weak start of the year, full year outlook maintained – regulated information

Written by Customer Service on May 14, 2024. Posted in Public Companies.

Regulated information – May 14, 2024 – 7:45 a.m. CET The Agfa-Gevaert Group in Q1 2024: weak start of the year, full year outlook maintained HealthCare IT: Soft quarter following a strong Q4 2023 Quarter-on-quarter improvement expected – stronger second half versus first half of the year Digital Print & Chemicals: Green Hydrogen Solutions business continued to grow substantially – ZIRFON plant project will be financed through leasing Effects of agreement with EFI and the launch of new printing equipment expected to show in the course of the year Film activities: continuous pressure from macro-economic conditions and currency impact Radiology Solutions: Reorganization go-to-market processes for medical film in China and overall destocking impact on Q1 sales volume Costs...

Edf: EDF announces the success of its senior multi-tranche bond issue for a nominal amount of CAD 750 million

Written by Customer Service on May 14, 2024. Posted in Public Companies.

EDF announces the success of its senior multi-tranche bond issue for a nominal amount of CAD 750 million On 13 May 2024: EDF (BBB stable S&P / Baa1 stable Moody’s / BBB+ stable Fitch) successfully priced a senior bond issuance in two tranches for a nominal amount of CAD 750 million (the “CAD Bonds”): CAD 350 million bond, with a 10-year maturity and a 5.379% fixed coupon; CAD400 million bond, with a 30-year maturity and a 5.777% fixed coupon; EDF is an active issuer of debt and other types of securities. EDF regularly assesses its financing requirements and monitors national and international financial markets for opportunities to conduct additional issuances of senior debt, hybrids and/or other types of securities. Settlement and delivery of the CAD Bonds is expected to take place on 17 May 2024. This transaction enables the...

Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer

Written by Customer Service on May 14, 2024. Posted in Public Companies.

OSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) — Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that it has expanded its collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA) to include a clinical trial collaboration and supply agreement for a phase 2 trial evaluating Nykode’s wholly-owned lead candidate, VB10.16, in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). This study will enroll HPV16-positive high-risk patients with locally advanced cervical cancer undergoing chemoradiotherapy. VB10.16 is a potentially first-in-class off-the-shelf therapeutic cancer vaccine specifically designed to treat HPV16-induced malignancies. The cancer vaccine is built on Nykode’s technology platform...

Aspo’s financial targets and dividend policy updated, and profitability metric of the guidance changed

Written by Customer Service on May 14, 2024. Posted in Public Companies.

Aspo PlcStock Exchange ReleaseOther information disclosed according to the rules of the ExchangeMay 14, 2024, at 8:05 a.m. Aspo’s financial targets and dividend policy updated, and profitability metric of the guidance changed Aspo holds a Capital Markets Day today, May 14, 2024, starting at 9.30 a.m. [(EEST)] in Helsinki. Aspo Group’s new portfolio vision, disclosed earlier today, along with the adjusted long-term financial targets, ESG commitment, business strategies, dividend policy as well as current state of Aspo’s business operations and prospects will be presented at the event. Revised financial targets Aspo’s long-term financial targets remain fundamentally unchanged, but they have been slightly adjusted to consider the compounder strategy and management of growth financing. Key changes include change from operating...

SalMar – Results in the first quarter characterized by a challenging winter period

Written by Customer Service on May 14, 2024. Posted in Earnings Releases And Operating Results.

Harsh winter conditions, extreme weather events and continued jellyfish attacks had adverse effect on SalMar’s farming segments in Norway in the first quarter and impacted the company’s results. Operational EBIT for Norway was NOK 1,546 million for the first quarter. Harvest volume was 45,400 tonnes and operational EBIT per kg was NOK 34.1. Operational EBIT for the Group was NOK 1,512 million for the first quarter. Harvest volume was 52,900 tonnes and operational EBIT per kg was NOK 28.6. The Salmon Living Lab innovation and R&D centre which was launched in the quarter has attracted broad interest from potential partners. “The first quarter was challenging in many ways, and we were once again reminded of the importance of working with the forces of nature. Our ability to understand biology and the environment is of great importance...

Nykode Therapeutics – Quarterly report Q1 2024

Written by Customer Service on May 14, 2024. Posted in Public Companies.

OSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) — Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced its unaudited financial results for the first quarter of 2024. The financial report can be accessed in the Investors section of the Company’s website: https://nykode.com/investors/financial-reports-and-presentations. The Company will host a webcast presentation at 4 p.m. CET / 10 a.m. ET. A live and archived webcast of the presentation can be accessed in the Investors section of the Company’s website and on the following link: https://event.webcasts.com/starthere.jsp?ei=1670178&tp_key=4faf9c3758 About Nykode TherapeuticsNykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and...

CoinShares Announces Q1 2024 Results: Achieving Its Most Successful Quarter in Company History

Written by Customer Service on May 14, 2024. Posted in Public Companies.

Q1 2024 Earnings Highlights: Revenue, gains, and other income increased by 216% YoY Over 4x YoY increase in adjusted EBITDA Total comprehensive income increased by over 11x YoY 14th May 2024 | SAINT HELIER, Jersey | CoinShares International Limited (“CoinShares” or “the Group”) (Nasdaq Stockholm: CS; US OTCQX: CNSRF), the leading European investment company specialising in digital assets, has today published its results for the quarter ending 31st March 2024. Jean-Marie Mognetti, Chief Executive Officer of CoinShares said: “Q1 2024 stands out as our strongest quarter ever, marking a period of unprecedented strength and profitability for CoinShares. This quarter reflects not only our robust financial performance but also highlights our enhanced strategic growth capabilities, exemplified by the successful acquisition of Valkyrie’s...

Author: Customer Service

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice